Trial Profile
Phase Ib/II Study of Enzalutamide With Venetoclax (ABT-199) in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Venetoclax (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Oct 2023 Status changed from active, no longer recruiting to completed.
- 21 Aug 2023 Planned End Date changed from 2 Aug 2023 to 2 Oct 2023.
- 18 Feb 2023 Results presented at the 2023 Genitourinary Cancers Symposium